{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:10Z","timestamp":1788966070154,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1248,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This multicentre, randomized, controlled, double-blind, parallel-group Phase III study was conducted to confirm the non-inferiority of OPC-61815 (tolvaptan sodium phosphate) intravenous injections to oral tolvaptan tablets in patients with congestive heart failure and volume overload despite receiving diuretics other than vasopressin antagonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Congestive heart failure patients with volume overload despite receiving diuretics other than vasopressin antagonists were randomly assigned (1:1) to receive OPC-61815 (16-mg injection; n = 149) or oral tolvaptan (15-mg tablet; n = 145) once daily for 5 days. Most patients were male; the mean age and weight were 74.7 years and 62.1 kg, respectively; other demographic and clinical characteristics were similar between groups. In this study, the primary endpoint was the change in body weight from baseline to the day after the last dose. Secondary endpoints included improvement from baseline in congestive findings and New York Heart Association classification. The change in body weight was \u22121.67 kg [95% confidence interval (CI): \u22121.93, \u22121.41] and \u22121.36 kg (95% CI: \u22121.62, \u22121.10) in the OPC-61815 group and tolvaptan group, respectively; the difference in the least squares mean between the groups was \u22120.31 kg (95% CI: \u22120.68, 0.06). Given the upper CI did not exceed the pre-specified limit of 0.48, this confirmed the non-inferiority of injectable OPC-61815 to oral tolvaptan. Daily urine volume and daily fluid intake increased, and daily fluid balance was negative throughout the treatment period; changes were similar for both groups. All evaluated congestive symptoms and New York Heart Association classifications showed improvement and safety findings were similar between the groups. The incidence of hyperkalaemia was higher in the OPC-61815 group, and the incidence of thirst and dry mouth was higher in the tolvaptan group. Most treatment-emergent adverse events were mild to moderate; one serious treatment-emergent adverse event of hyperkalaemia in the OPC-61815 group was considered treatment related.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OPC-61815 (16-mg injection) was confirmed as non-inferior to oral tolvaptan (15-mg tablet) in patients with congestive heart failure and inadequate response to diuretics; no new safety concerns were observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14021","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T22:05:20Z","timestamp":1657145120000},"page":"3275-3286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Intravenous OPC-61815 Compared with Oral Tolvaptan in Patients with Congestive Heart Failure"],"prefix":"10.1093","volume":"9","author":[{"given":"Naoki","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kawaguchi Cardiovascular and Respiratory Hospital , Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Uno","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development, Otsuka Pharmaceutical Co. Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kurita","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Otsuka Pharmaceutical Co. Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongryul","family":"Kim","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development, Otsuka Pharmaceutical Co. Ltd. , Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the OPTION-HF Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"2026012114162224500_ehf214021-bib-0001","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114162224500_ehf214021-bib-0002","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure \u2013 Digest version","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"2026012114162224500_ehf214021-bib-0003","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2174\/1389450116666150420125531","article-title":"Loop diuretics strategies in acute heart failure: From clinical trials to practical application","volume":"16","author":"Palazzuoli","year":"2015","journal-title":"Curr Drug Targets"},{"key":"2026012114162224500_ehf214021-bib-0004","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1253\/circj.CJ-13-0187","article-title":"Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry)","volume":"77","author":"Sato","year":"2013","journal-title":"Circ J"},{"key":"2026012114162224500_ehf214021-bib-0005","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1253\/circj.CJ-17-1386","article-title":"Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan \u2015 observations from the prospective, multicenter Kyoto congestive heart failure (KCHF) registry","volume":"82","author":"Yaku","year":"2018","journal-title":"Circ J"},{"key":"2026012114162224500_ehf214021-bib-0006","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ehf2.13139","article-title":"Time-sensitive approach in the management of acute heart failure","volume":"8","author":"Shiraishi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114162224500_ehf214021-bib-0007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion \u2013 A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114162224500_ehf214021-bib-0008","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114162224500_ehf214021-bib-0009","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.04.042","article-title":"Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure","volume":"69","author":"Matsue","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012114162224500_ehf214021-bib-0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in heart failure: A contemporary look at physiology, diagnosis and treatment","volume":"17","author":"Boorsma","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026012114162224500_ehf214021-bib-0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ehf2.12088","article-title":"Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure","volume":"3","author":"Jujo","year":"2016","journal-title":"ESC Heart Fail"},{"key":"2026012114162224500_ehf214021-bib-0012","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ehf2.12690","article-title":"Impact of adjunctive tolvaptan on sympathetic activity in acute heart failure with preserved ejection fraction","volume":"7","author":"Tamaki","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026012114162224500_ehf214021-bib-0013","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012114162224500_ehf214021-bib-0014","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25","author":"Matsuzaki","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012114162224500_ehf214021-bib-0015","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1253\/circj.CJ-19-0158","article-title":"Real-world effectiveness and tolerability of tolvaptan in patients with heart failure \u2013 Final results of the Samsca post-marketing surveillance in heart failure (SMILE) study","volume":"83","author":"Kinugawa","year":"2019","journal-title":"Circ J"},{"key":"2026012114162224500_ehf214021-bib-0016","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"2026012114162224500_ehf214021-bib-0017","volume-title":"Tolvaptan (SAMSCA) tablets, orally disintegrating tablets, and granules [Japanese package insert]","year":"2021","edition":"Second edition"},{"key":"2026012114162224500_ehf214021-bib-0018","first-page":"e147","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"2013","author":"Yancy","journal-title":"J Am Coll Cardiol"},{"key":"2026012114162224500_ehf214021-bib-0019","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/ehf2.12305","article-title":"Acute heart failure management in the USA and Japan: Overview of practice patterns and review of evidence","volume":"5","author":"Tanaka","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012114162224500_ehf214021-bib-0020","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ehf2.13111","article-title":"Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan","volume":"8","author":"Kuragaichi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114162224500_ehf214021-bib-0021","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic treatment in heart failure","volume":"377","author":"Ellison","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114162224500_ehf214021-bib-0022","article-title":"Pharmacokinetics, pharmacodynamics and efficacy of OPC-61815, prodrug of tolvaptan for intravenous administration, in patients with congestive heart failure \u2015 A phase II, multicenter, double-blind, randomized, active-controlled trial","author":"Sato","year":"2021","journal-title":"Circ J"},{"key":"2026012114162224500_ehf214021-bib-0023","volume-title":"ICH harmonised guideline integrated addendum to ICH E6(R1): Guideline for good clinical practice ICH E6(R2) ICH consensus guideline"},{"key":"2026012114162224500_ehf214021-bib-0024","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11897-019-0424-1","article-title":"Diuretic resistance in heart failure","volume":"16","author":"Gupta","year":"2019","journal-title":"Curr Heart Fail Rep"},{"key":"2026012114162224500_ehf214021-bib-0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40262-014-0194-6","article-title":"Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: A pharmacokinetic and pharmacodynamic study","volume":"54","author":"Kida","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2026012114162224500_ehf214021-bib-0026","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s11255-019-02180-8","article-title":"Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients","volume":"51","author":"Masuda","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"2026012114162224500_ehf214021-bib-0027","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/1755-5922.12142","article-title":"The efficacy of tolvaptan in congestive heart failure patients with and without hypoalbuminemia: A pilot study","volume":"33","author":"Okabe","year":"2015","journal-title":"Cardiovasc Ther"},{"key":"2026012114162224500_ehf214021-bib-0028","doi-asserted-by":"crossref","DOI":"10.1253\/circj.CJ-21-0926","article-title":"Tolerability of the intravenously administered tolvaptan prodrug, OPC-61815, in patients with congestive heart failure who have difficulty with, or are incapable of, oral intake (TRITON-HF)","author":"Kinugawa","year":"2022","journal-title":"Circ J"},{"key":"2026012114162224500_ehf214021-bib-0029","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3275\/65352381\/eschf_9_5_3275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/5\/3275\/65352381\/eschf_9_5_3275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:19:38Z","timestamp":1769023178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/5\/3275\/8323078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,7,6]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14021","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"2022-02-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}